(Date:11/24/2009)... REYKJAVIK, Iceland, November 24 /PRNewswire-Fi...today announced the approval of all of its,"first ...District of Delaware,(the "Bankruptcy Court"). deC...f under Chapter 11 of the United States Bankruptcy...ders issued by the Bankruptcy Court allow the comp...
(Date:11/24/2009)...GHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolax...nistration (SFDA) has approved the,investigational...roject,(Nodlin), an innovative insulin formulation...xy to initiate its first phase I clinical study. ,... high blood glucose and poor,metabolism. The compl...
(Date:11/24/2009)... efficacy endpoint has been met for patients with ..., , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCal...EZ) (the "Company"), a global biopharmaceutical co...oday announced positive efficacy data from a Phase...gate, AEZS-108 (formerly AN-152), in patients with...
(Date:11/24/2009)..., Nov. 24, 2009 Arena Ph...oday that the company is scheduled to present at t...e on December 1, 2009 at 11:30 a.m. Eastern Time (...el in New York City. Jack Lief, Arena,s President ...de an overview of the company, including its clini...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3...enta,Incorporated (OTC Bulletin Board: GNTA) today... June 30, 2008. The Company recorded significant,m...lowing:, -- NDA amendment for Genasense(R) in CLL...asense in melanoma updated at EADO, -- Clinical h...axane,lifted by FDA, -- Pharmacokinetics of or...
...stretchable optoelectronics and biologically inspi...maging device, with a layout based on the human ey... Nature, researchers at the University of Illino...gh-performance, hemispherical "eye" camera using a...d electronics, configured in a stretchable, interc...
...r service revenue grows approximately 33% ... - Operating margin of 9.9% for the quarter,- Rec...atio of 1.56 for the ...Corporation (Nasdaq: PRXL ) today announced its f... Year ended June 30, 2008., For the three months ...
Other Biology Technology:Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 8Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 9Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights 10Stretchable silicon camera next step to artificial retina 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14Donor feline Serum - 100mL from Biomeda Corporation
Monocyte Activation Kit from 3H Biomedical AB
Goat Anti-NPT1 (M-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Suction Cups and Assemblies from Parker Hannifin Corporation
Biology Products: